Navigation Links
REGiMMUNE to present GvHD data at the 50th ASH Annual Meeting
Date:12/5/2008

Mountain View, CA December 5, 2008 REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, will present preclinical data on the company's potential therapeutic treatment for Graft versus Host Disease (GvHD) at the American Society of Hematology Annual Meeting being held December 6 through 9 in San Francisco, California. REGiMMUNE is developing KRN7000 (RGI-2001) as a new immunosuppressant for GvHD associated with stem cell transplantation. Two posters will be presented at ASH on the evenings of Sunday December 7 and Monday December 8, respectively.

Abstract/Poster II-426
Sunday, December 7: 6:00 PM - 8:00 PM
Donor-Specific Tolerance Induction through Expansion of DCregs and Tregs by a Liposomal Formulation of KRN7000 (RGI-2001)

Abstract/Poster III-582
Monday, December 8: 5:30 PM - 7:30 PM
A Liposomal Formulation of KRN7000 (RGI-2001) Potently Reduces GvHD Lethality through the Expansion of CD4+Foxp3+ Regulatory T cells in Murine Models.

"We are delighted to present our progress on RGI-2001 development at the 50th ASH Annual Meeting," said Mr. Haru Morita, President and Chief Executive Officer, REGiMMUNE. "This is a great opportunity to provide an update on our pre-IND stage product candidate, RGI-2001, which is in a preclinical study for GvHD associated with bone marrow transplantation. The company is also developing RGI-2001 for solid organ transplantation. Our mission is to develop novel therapies for immune disorders including allergies, autoimmune diseases and transplantation. We believe the success of RGI-2001 will be the first demonstration of the promise of our proprietary technology and of the company's significant development capabilities."


'/>"/>

Contact: Debra Bannister
530-676-8001
REGiMMUNE
Source:Eurekalert

Page: 1

Related medicine news :

1. 11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions
2. Aflac Incorporated To Present at the Goldman Sachs U.S. Financial Services Conference 2008
3. Inverness Medical Innovations to Present at RBC Capital Markets 2008 Healthcare Conference on December 11, 2008
4. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
5. Zevalin Data to be Presented at ASH 2008
6. MAP Pharmaceuticals to Present at the 2008 RBC Capital Markets Healthcare Conference
7. Medicsight PLC Presents New Data at RSNA 2008 Further Supporting Relevance of Computer-Aided Detection (CAD) and Image Analysis Software in Early Colon Cancer Screening and Diagnosis
8. Cardium Announces Investor Presentation and Corporate Update Webcast
9. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society of Hematology Annual Meeting
10. LCA-Vision to Present at RBC Capital Markets 2008 Healthcare Conference
11. Quark Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... September 25, 2017 , ... Catalent ... for drugs, biologics and consumer health products, today announced that two of its ... of bioassays at two upcoming conferences. , At the BEBPA 10th Annual Bioassay ...
(Date:9/25/2017)... ... ... NCPDP Foundation , a 501(c)(3) nonprofit charitable organization ... grant to Johns Hopkins Medicine to address patient safety risk by implementing CancelRx ... a prescription already submitted to a pharmacy. Studies indicate that up to 3% ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean ... efficiency. The principle of First-Defect-Stop for laboratory weighing is designed to ... the chance to have negative consequences on downstream processes. , If a problem ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... technology-enabled services supporting clinical research, today announces that 30 of its domain ... the drug development lifecycle at upcoming industry conferences and webinars. Drawing on ...
(Date:9/25/2017)... ... September 25, 2017 , ... Ron Norman, CEO of Team ... upper-level executives speaking at a business luncheon today, "It is tantamount to forgetting ... asset to be fully realized and activated by the corporations that recognize their ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... , Sept. 7, 2017  Zimmer Biomet Holdings, ... musculoskeletal healthcare, today announced that it will be participating ... Healthcare Conference at the Grand Hyatt hotel in New ... 2017 at 11:40 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
Breaking Medicine Technology: